Amit Ghate
Long/short equity, value

Osiris - An Impressive Short Squeeze Leads To A Potential Shorting Opportunity

Osiris Therapeutics (NASDAQ:OSIR) on Tuesday, Aug 13 announced fantastic top line results from its Grafix phase III clinical trial for the treatment of chronic diabetic foot ulcers (DFUs). The trial met all primary and secondary endpoints, and did so convincingly that the trial was stopped for overwhelming efficacy. A summary of the top line results are reproduced below:

(click to enlarge)

The effect that these results had on the share price was (at least in my opinion) magnified by the significant short interest and low daily volume the stock carried with it. Below is Yahoo's reporting of the stock's "trading information" coming into the day.

With 16.5% of the float short and an impressive 30 days to...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details